Latest Universal Biosensors (ASX:UBI) News

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Universal Biosensors has secured a Vendor Master Purchase Agreement with Chewy and launched its Petrackr veterinary glucose monitoring system on Amazon, positioning itself for significant growth in North America's online pet care market.